Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Advise patients and caregivers that serious systemic hypersensitivity reactions (anaphylaxis and angioedema) are possible and that prompt medical attention should be sought if an allergic reaction occurs [see Warnings and Precautions (5.2)].
Advise childhood cancer survivors and caregivers that individuals treated with radiation to the head are at increased risk of secondary neoplasms and, as a precaution, need to be monitored for recurrence. Advise patients to report marked changes in skin pigmentation or changes in the appearance of preexisting nevi [see Warnings and Precautions (5.3)].
Advise patients and caregivers that new onset of insulin resistance and hyperglycemia may occur and monitoring of blood glucose during treatment with NGENLA in patients with glucose intolerance or who have risk factors for diabetes, may be needed [see Warnings and Precautions (5.4)].
Advise patients and caregivers to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting [see Warnings and Precautions (5.5)].
Advise patients and caregivers that fluid retention during NGENLA therapy may occur. Inform patients of the clinical manifestations of fluid retention (e.g. edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paresthesia) and to report to their healthcare provider if any of these signs or symptoms occur during treatment with NGENLA.
Advise patients and caregivers who have or who are at risk for corticotropin deficiency that hypoadrenalism may develop and to report to their healthcare provider if extreme fatigue, dizziness, weakness, vomiting, dehydration or weight loss is experienced during treatment with NGENLA [see Warnings and Precautions (5.7)].
Advise patients and caregivers that undiagnosed/untreated hypothyroidism may prevent an optimal response to NGENLA. Advise patients and caregivers they may require periodic thyroid function tests during treatment with NGENLA [see Warnings and Precautions (5.8)].
Advise patients and caregivers that pancreatitis may develop and to report to their healthcare provider any new onset persistent severe abdominal pain.
Advise patients and caregivers that lipoatrophy may occur if NGENLA is administered subcutaneously at the same site over a long period of time. Advise patients to rotate injection sites when administering NGENLA to reduce this risk.
This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 6/2023 |
PATIENT INFORMATION (somatrogon-ghla) injection, for subcutaneous use |
What is NGENLA? |
Do not use NGENLA if:
|
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works. |
How should I use NGENLA?
|
What are the possible side effects of NGENLA? NGENLA may cause serious side effects, including:
The most common side effects of NGENLA include:
These are not all the possible side effects of NGENLA. You should tell your child’s healthcare provider if your child has any side effect that bothers them or that does not go away. |
How should I store NGENLA?
Before you use NGENLA pens for the first time (unused pens):
After you use NGENLA pens and there is still medicine left (up to 28 days of use):
Keep NGENLA and all medicines out of the reach of children. |
General information about the safe and effective use of NGENLA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NGENLA for a condition for which it was not prescribed. Do not give NGENLA to other people, even if they have the same symptoms because it may harm them. You can ask your pharmacist or healthcare provider for information about NGENLA that is written for health professionals. |
What are the ingredients in NGENLA? Active ingredient: somatrogon-ghla
|
NGENLA (en’ JEN-lah)
(somatrogon-ghla)
24 mg
injection, for subcutaneous use
Read this Instructions for Use before you start using NGENLA and each time you get a new refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Important information about your NGENLA pen:
Supplies you will need each time you inject
Included in the carton:
Not included in the carton:
24 mg NGENLA pen:
Needles to use
Pen needles are not included with your NGENLA pen. You will need a prescription from your healthcare provider to get pen needles up to a length of 8 mm from your pharmacy. Talk with your healthcare provider about the right needle for you.
Sterile needle (example) not supplied:
Sterile needle with safety shield (example) not supplied:
Note: Needles with safety shield do not have an inner needle cap. Steps 5, 6 and 11 within these instructions relating to the inner needle cap may not apply when using a needle with safety shield. Refer to the safety shield needle manufacturer’s instructions for use (IFU) for more information on attaching and removing the safety needle. When using safety shield needles, priming is required only for the first use of a new pen; follow the NGENLA pen IFU for priming.
Caution: Never use a bent or damaged needle. Always handle pen needles with care to make sure you do not prick yourself (or anyone else) with the needle. Do not attach a new needle to your pen until you are ready to take your injection.
Preparing for your injection
Step 1 - Getting ready
Step 2 - Choose and clean your injection site
Step 3 - Check medicine
Step 5 - Pull off outer needle cover
Step 6 - Pull off inner needle cap
Is this pen new?
Yes: Go to new pen set up (arrow directing to “New pen set up (priming) - for the first use of a new pen only”)
No (arrow directing to “Setting your prescribed dose”)
New pen set up (priming) – for the first use of a new pen only
You must set up each new pen (priming) before using it for the first time
A - Set priming dose
B - Tap cartridge holder
C - Press button and check for liquid
Setting your prescribed dose
Step 7 - Set your dose
3.8 mg shown in the dose window
12.0 mg shown in the dose window
What should I do if I cannot set the dose I need?
What should I do if I do not have enough medicine left in my pen?
Only split your dose if you have been trained or told by your healthcare provider on how to do this.
Injecting your dose
Step 8 - Insert the needle
Step 9 - Inject your medicine
Step 10 - Count to 10
Step 11 - Attach outer needle cover
Step 12 - Remove the needle
Step 13 - Replace the pen cap
Step 14 - After your injection
Storage and disposal:
Before first use (unused pens):
After first use (up to 28 days of use):
Date of first use ______ / ______ / ______
How should I dispose of the pen needles and pens?
Manufactured by:
Pfizer Ireland Pharmaceuticals
Ringaskiddy,
Cork,
Ireland
US License No: 2060
LAB-1452-2.0
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: 7/2024
Instructions for Use
NGENLA (en’ JEN-lah)
(somatrogon-ghla)
60 mg
injection, for subcutaneous use
Read this Instructions for Use before you start using NGENLA and each time you get a new refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Important information about your NGENLA pen:
Supplies you will need each time you inject
Included in the carton:
Not included in the carton:
60 mg NGENLA pen:
Needles to use
Pen needles are not included with your NGENLA pen. You will need a prescription from your healthcare provider to get pen needles up to a length of 8 mm from your pharmacy. Talk with your healthcare provider about the right needle for you.
Sterile needle (example) not supplied:
Sterile needle with safety shield (example) not supplied:
Note: Needles with safety shield do not have an inner needle cap. Steps 5, 6 and 11 within these instructions relating to the inner needle cap may not apply when using a needle with safety shield. Refer to the safety shield needle manufacturer’s instructions for use (IFU) for more information on attaching and removing the safety needle. When using safety shield needles, priming is required only for the first use of a new pen; follow the NGENLA pen IFU for priming.
Caution: Never use a bent or damaged needle. Always handle pen needles with care to make sure you do not prick yourself (or anyone else) with the needle. Do not attach a new needle to your pen until you are ready to take your injection.
Preparing for your injection
Step 1 - Getting ready
Step 2 - Choose and clean your injection site
Step 3 - Check medicine
Step 5 - Pull off outer needle cover
Step 6 - Pull off inner needle cap
Is this pen new?
Yes: Go to new pen set up (arrow directing to “New pen set up (priming) - for the first use of a new pen only”)
No (arrow directing to “Setting your prescribed dose”)
New pen set up (priming) – for the first use of a new pen only
You must set up each new pen (priming) before using it for the first time
A - Set priming dose
B - Tap cartridge holder
C - Press button and check for liquid
Setting your prescribed dose
Step 7 - Set your dose
21.5 mg shown in the dose window
30.0 mg shown in the dose window
What should I do if I cannot set the dose I need?
What should I do if I do not have enough medicine left in my pen?
Only split your dose if you have been trained or told by your healthcare provider on how to do this.
Injecting your dose
Step 8 - Insert the needle
Step 9 - Inject your medicine
Step 10 - Count to 10
Step 11 - Attach outer needle cover
Step 12 - Remove the needle
Step 13 - Replace the pen cap
Step 14 - After your injection
Storage and disposal:
Before first use (unused pens):
After first use (up to 28 days of use):
Date of first use ______ / ______ / ______
How should I dispose of the pen needles and pens?
Manufactured by:
Pfizer Ireland Pharmaceuticals
Ringaskiddy,
Cork,
Ireland
US License No: 2060
LAB-1454-2.0
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: 7/2024
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Advise patients and caregivers that serious systemic hypersensitivity reactions (anaphylaxis and angioedema) are possible and that prompt medical attention should be sought if an allergic reaction occurs [see Warnings and Precautions (5.2)].
Advise childhood cancer survivors and caregivers that individuals treated with radiation to the head are at increased risk of secondary neoplasms and, as a precaution, need to be monitored for recurrence. Advise patients to report marked changes in skin pigmentation or changes in the appearance of preexisting nevi [see Warnings and Precautions (5.3)].
Advise patients and caregivers that new onset of insulin resistance and hyperglycemia may occur and monitoring of blood glucose during treatment with NGENLA in patients with glucose intolerance or who have risk factors for diabetes, may be needed [see Warnings and Precautions (5.4)].
Advise patients and caregivers to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting [see Warnings and Precautions (5.5)].
Advise patients and caregivers that fluid retention during NGENLA therapy may occur. Inform patients of the clinical manifestations of fluid retention (e.g. edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paresthesia) and to report to their healthcare provider if any of these signs or symptoms occur during treatment with NGENLA.
Advise patients and caregivers who have or who are at risk for corticotropin deficiency that hypoadrenalism may develop and to report to their healthcare provider if extreme fatigue, dizziness, weakness, vomiting, dehydration or weight loss is experienced during treatment with NGENLA [see Warnings and Precautions (5.7)].
Advise patients and caregivers that undiagnosed/untreated hypothyroidism may prevent an optimal response to NGENLA. Advise patients and caregivers they may require periodic thyroid function tests during treatment with NGENLA [see Warnings and Precautions (5.8)].
Advise patients and caregivers that pancreatitis may develop and to report to their healthcare provider any new onset persistent severe abdominal pain.
Advise patients and caregivers that lipoatrophy may occur if NGENLA is administered subcutaneously at the same site over a long period of time. Advise patients to rotate injection sites when administering NGENLA to reduce this risk.
This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 6/2023 |
PATIENT INFORMATION (somatrogon-ghla) injection, for subcutaneous use |
What is NGENLA? |
Do not use NGENLA if:
|
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works. |
How should I use NGENLA?
|
What are the possible side effects of NGENLA? NGENLA may cause serious side effects, including:
The most common side effects of NGENLA include:
These are not all the possible side effects of NGENLA. You should tell your child’s healthcare provider if your child has any side effect that bothers them or that does not go away. |
How should I store NGENLA?
Before you use NGENLA pens for the first time (unused pens):
After you use NGENLA pens and there is still medicine left (up to 28 days of use):
Keep NGENLA and all medicines out of the reach of children. |
General information about the safe and effective use of NGENLA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NGENLA for a condition for which it was not prescribed. Do not give NGENLA to other people, even if they have the same symptoms because it may harm them. You can ask your pharmacist or healthcare provider for information about NGENLA that is written for health professionals. |
What are the ingredients in NGENLA? Active ingredient: somatrogon-ghla
|
NGENLA (en’ JEN-lah)
(somatrogon-ghla)
24 mg
injection, for subcutaneous use
Read this Instructions for Use before you start using NGENLA and each time you get a new refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Important information about your NGENLA pen:
Supplies you will need each time you inject
Included in the carton:
Not included in the carton:
24 mg NGENLA pen:
Needles to use
Pen needles are not included with your NGENLA pen. You will need a prescription from your healthcare provider to get pen needles up to a length of 8 mm from your pharmacy. Talk with your healthcare provider about the right needle for you.
Sterile needle (example) not supplied:
Sterile needle with safety shield (example) not supplied:
Note: Needles with safety shield do not have an inner needle cap. Steps 5, 6 and 11 within these instructions relating to the inner needle cap may not apply when using a needle with safety shield. Refer to the safety shield needle manufacturer’s instructions for use (IFU) for more information on attaching and removing the safety needle. When using safety shield needles, priming is required only for the first use of a new pen; follow the NGENLA pen IFU for priming.
Caution: Never use a bent or damaged needle. Always handle pen needles with care to make sure you do not prick yourself (or anyone else) with the needle. Do not attach a new needle to your pen until you are ready to take your injection.
Preparing for your injection
Step 1 - Getting ready
Step 2 - Choose and clean your injection site
Step 3 - Check medicine
Step 5 - Pull off outer needle cover
Step 6 - Pull off inner needle cap
Is this pen new?
Yes: Go to new pen set up (arrow directing to “New pen set up (priming) - for the first use of a new pen only”)
No (arrow directing to “Setting your prescribed dose”)
New pen set up (priming) – for the first use of a new pen only
You must set up each new pen (priming) before using it for the first time
A - Set priming dose
B - Tap cartridge holder
C - Press button and check for liquid
Setting your prescribed dose
Step 7 - Set your dose
3.8 mg shown in the dose window
12.0 mg shown in the dose window
What should I do if I cannot set the dose I need?
What should I do if I do not have enough medicine left in my pen?
Only split your dose if you have been trained or told by your healthcare provider on how to do this.
Injecting your dose
Step 8 - Insert the needle
Step 9 - Inject your medicine
Step 10 - Count to 10
Step 11 - Attach outer needle cover
Step 12 - Remove the needle
Step 13 - Replace the pen cap
Step 14 - After your injection
Storage and disposal:
Before first use (unused pens):
After first use (up to 28 days of use):
Date of first use ______ / ______ / ______
How should I dispose of the pen needles and pens?
Manufactured by:
Pfizer Ireland Pharmaceuticals
Ringaskiddy,
Cork,
Ireland
US License No: 2060
LAB-1452-2.0
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: 7/2024
Instructions for Use
NGENLA (en’ JEN-lah)
(somatrogon-ghla)
60 mg
injection, for subcutaneous use
Read this Instructions for Use before you start using NGENLA and each time you get a new refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Important information about your NGENLA pen:
Supplies you will need each time you inject
Included in the carton:
Not included in the carton:
60 mg NGENLA pen:
Needles to use
Pen needles are not included with your NGENLA pen. You will need a prescription from your healthcare provider to get pen needles up to a length of 8 mm from your pharmacy. Talk with your healthcare provider about the right needle for you.
Sterile needle (example) not supplied:
Sterile needle with safety shield (example) not supplied:
Note: Needles with safety shield do not have an inner needle cap. Steps 5, 6 and 11 within these instructions relating to the inner needle cap may not apply when using a needle with safety shield. Refer to the safety shield needle manufacturer’s instructions for use (IFU) for more information on attaching and removing the safety needle. When using safety shield needles, priming is required only for the first use of a new pen; follow the NGENLA pen IFU for priming.
Caution: Never use a bent or damaged needle. Always handle pen needles with care to make sure you do not prick yourself (or anyone else) with the needle. Do not attach a new needle to your pen until you are ready to take your injection.
Preparing for your injection
Step 1 - Getting ready
Step 2 - Choose and clean your injection site
Step 3 - Check medicine
Step 5 - Pull off outer needle cover
Step 6 - Pull off inner needle cap
Is this pen new?
Yes: Go to new pen set up (arrow directing to “New pen set up (priming) - for the first use of a new pen only”)
No (arrow directing to “Setting your prescribed dose”)
New pen set up (priming) – for the first use of a new pen only
You must set up each new pen (priming) before using it for the first time
A - Set priming dose
B - Tap cartridge holder
C - Press button and check for liquid
Setting your prescribed dose
Step 7 - Set your dose
21.5 mg shown in the dose window
30.0 mg shown in the dose window
What should I do if I cannot set the dose I need?
What should I do if I do not have enough medicine left in my pen?
Only split your dose if you have been trained or told by your healthcare provider on how to do this.
Injecting your dose
Step 8 - Insert the needle
Step 9 - Inject your medicine
Step 10 - Count to 10
Step 11 - Attach outer needle cover
Step 12 - Remove the needle
Step 13 - Replace the pen cap
Step 14 - After your injection
Storage and disposal:
Before first use (unused pens):
After first use (up to 28 days of use):
Date of first use ______ / ______ / ______
How should I dispose of the pen needles and pens?
Manufactured by:
Pfizer Ireland Pharmaceuticals
Ringaskiddy,
Cork,
Ireland
US License No: 2060
LAB-1454-2.0
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: 7/2024
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Advise patients and caregivers that serious systemic hypersensitivity reactions (anaphylaxis and angioedema) are possible and that prompt medical attention should be sought if an allergic reaction occurs [see Warnings and Precautions (5.2)].
Advise childhood cancer survivors and caregivers that individuals treated with radiation to the head are at increased risk of secondary neoplasms and, as a precaution, need to be monitored for recurrence. Advise patients to report marked changes in skin pigmentation or changes in the appearance of preexisting nevi [see Warnings and Precautions (5.3)].
Advise patients and caregivers that new onset of insulin resistance and hyperglycemia may occur and monitoring of blood glucose during treatment with NGENLA in patients with glucose intolerance or who have risk factors for diabetes, may be needed [see Warnings and Precautions (5.4)].
Advise patients and caregivers to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting [see Warnings and Precautions (5.5)].
Advise patients and caregivers that fluid retention during NGENLA therapy may occur. Inform patients of the clinical manifestations of fluid retention (e.g. edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paresthesia) and to report to their healthcare provider if any of these signs or symptoms occur during treatment with NGENLA.
Advise patients and caregivers who have or who are at risk for corticotropin deficiency that hypoadrenalism may develop and to report to their healthcare provider if extreme fatigue, dizziness, weakness, vomiting, dehydration or weight loss is experienced during treatment with NGENLA [see Warnings and Precautions (5.7)].
Advise patients and caregivers that undiagnosed/untreated hypothyroidism may prevent an optimal response to NGENLA. Advise patients and caregivers they may require periodic thyroid function tests during treatment with NGENLA [see Warnings and Precautions (5.8)].
Advise patients and caregivers that pancreatitis may develop and to report to their healthcare provider any new onset persistent severe abdominal pain.
Advise patients and caregivers that lipoatrophy may occur if NGENLA is administered subcutaneously at the same site over a long period of time. Advise patients to rotate injection sites when administering NGENLA to reduce this risk.
This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 6/2023 |
PATIENT INFORMATION (somatrogon-ghla) injection, for subcutaneous use |
What is NGENLA? |
Do not use NGENLA if:
|
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works. |
How should I use NGENLA?
|
What are the possible side effects of NGENLA? NGENLA may cause serious side effects, including:
The most common side effects of NGENLA include:
These are not all the possible side effects of NGENLA. You should tell your child’s healthcare provider if your child has any side effect that bothers them or that does not go away. |
How should I store NGENLA?
Before you use NGENLA pens for the first time (unused pens):
After you use NGENLA pens and there is still medicine left (up to 28 days of use):
Keep NGENLA and all medicines out of the reach of children. |
General information about the safe and effective use of NGENLA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NGENLA for a condition for which it was not prescribed. Do not give NGENLA to other people, even if they have the same symptoms because it may harm them. You can ask your pharmacist or healthcare provider for information about NGENLA that is written for health professionals. |
What are the ingredients in NGENLA? Active ingredient: somatrogon-ghla
|
NGENLA (en’ JEN-lah)
(somatrogon-ghla)
24 mg
injection, for subcutaneous use
Read this Instructions for Use before you start using NGENLA and each time you get a new refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Important information about your NGENLA pen:
Supplies you will need each time you inject
Included in the carton:
Not included in the carton:
24 mg NGENLA pen:
Needles to use
Pen needles are not included with your NGENLA pen. You will need a prescription from your healthcare provider to get pen needles up to a length of 8 mm from your pharmacy. Talk with your healthcare provider about the right needle for you.
Sterile needle (example) not supplied:
Sterile needle with safety shield (example) not supplied:
Note: Needles with safety shield do not have an inner needle cap. Steps 5, 6 and 11 within these instructions relating to the inner needle cap may not apply when using a needle with safety shield. Refer to the safety shield needle manufacturer’s instructions for use (IFU) for more information on attaching and removing the safety needle. When using safety shield needles, priming is required only for the first use of a new pen; follow the NGENLA pen IFU for priming.
Caution: Never use a bent or damaged needle. Always handle pen needles with care to make sure you do not prick yourself (or anyone else) with the needle. Do not attach a new needle to your pen until you are ready to take your injection.
Preparing for your injection
Step 1 - Getting ready
Step 2 - Choose and clean your injection site
Step 3 - Check medicine
Step 5 - Pull off outer needle cover
Step 6 - Pull off inner needle cap
Is this pen new?
Yes: Go to new pen set up (arrow directing to “New pen set up (priming) - for the first use of a new pen only”)
No (arrow directing to “Setting your prescribed dose”)
New pen set up (priming) – for the first use of a new pen only
You must set up each new pen (priming) before using it for the first time
A - Set priming dose
B - Tap cartridge holder
C - Press button and check for liquid
Setting your prescribed dose
Step 7 - Set your dose
3.8 mg shown in the dose window
12.0 mg shown in the dose window
What should I do if I cannot set the dose I need?
What should I do if I do not have enough medicine left in my pen?
Only split your dose if you have been trained or told by your healthcare provider on how to do this.
Injecting your dose
Step 8 - Insert the needle
Step 9 - Inject your medicine
Step 10 - Count to 10
Step 11 - Attach outer needle cover
Step 12 - Remove the needle
Step 13 - Replace the pen cap
Step 14 - After your injection
Storage and disposal:
Before first use (unused pens):
After first use (up to 28 days of use):
Date of first use ______ / ______ / ______
How should I dispose of the pen needles and pens?
Manufactured by:
Pfizer Ireland Pharmaceuticals
Ringaskiddy,
Cork,
Ireland
US License No: 2060
LAB-1452-2.0
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: 7/2024
Instructions for Use
NGENLA (en’ JEN-lah)
(somatrogon-ghla)
60 mg
injection, for subcutaneous use
Read this Instructions for Use before you start using NGENLA and each time you get a new refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Important information about your NGENLA pen:
Supplies you will need each time you inject
Included in the carton:
Not included in the carton:
60 mg NGENLA pen:
Needles to use
Pen needles are not included with your NGENLA pen. You will need a prescription from your healthcare provider to get pen needles up to a length of 8 mm from your pharmacy. Talk with your healthcare provider about the right needle for you.
Sterile needle (example) not supplied:
Sterile needle with safety shield (example) not supplied:
Note: Needles with safety shield do not have an inner needle cap. Steps 5, 6 and 11 within these instructions relating to the inner needle cap may not apply when using a needle with safety shield. Refer to the safety shield needle manufacturer’s instructions for use (IFU) for more information on attaching and removing the safety needle. When using safety shield needles, priming is required only for the first use of a new pen; follow the NGENLA pen IFU for priming.
Caution: Never use a bent or damaged needle. Always handle pen needles with care to make sure you do not prick yourself (or anyone else) with the needle. Do not attach a new needle to your pen until you are ready to take your injection.
Preparing for your injection
Step 1 - Getting ready
Step 2 - Choose and clean your injection site
Step 3 - Check medicine
Step 5 - Pull off outer needle cover
Step 6 - Pull off inner needle cap
Is this pen new?
Yes: Go to new pen set up (arrow directing to “New pen set up (priming) - for the first use of a new pen only”)
No (arrow directing to “Setting your prescribed dose”)
New pen set up (priming) – for the first use of a new pen only
You must set up each new pen (priming) before using it for the first time
A - Set priming dose
B - Tap cartridge holder
C - Press button and check for liquid
Setting your prescribed dose
Step 7 - Set your dose
21.5 mg shown in the dose window
30.0 mg shown in the dose window
What should I do if I cannot set the dose I need?
What should I do if I do not have enough medicine left in my pen?
Only split your dose if you have been trained or told by your healthcare provider on how to do this.
Injecting your dose
Step 8 - Insert the needle
Step 9 - Inject your medicine
Step 10 - Count to 10
Step 11 - Attach outer needle cover
Step 12 - Remove the needle
Step 13 - Replace the pen cap
Step 14 - After your injection
Storage and disposal:
Before first use (unused pens):
After first use (up to 28 days of use):
Date of first use ______ / ______ / ______
How should I dispose of the pen needles and pens?
Manufactured by:
Pfizer Ireland Pharmaceuticals
Ringaskiddy,
Cork,
Ireland
US License No: 2060
LAB-1454-2.0
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: 7/2024
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.